Insulet (NASDAQ:PODD – Get Free Report) had its price objective boosted by analysts at Piper Sandler from $285.00 to $310.00 ...
Insulet (NASDAQ:PODD – Get Free Report)‘s stock had its “outperform” rating restated by equities research analysts at Raymond ...
Shares of Insulet Corp. PODD slid 1.90% to $282.80 Friday, on what proved to be an all-around dismal trading session for the ...
2d
Zacks.com on MSNPODD Stock Falls Despite Q4 Earnings and Revenue Beat, Margins RiseInsulet Corporation PODD reported fourth-quarter 2024 adjusted earnings per share (EPS) of $1.15, down significantly 17.8% ...
Analysts have been eager to weigh in on the Healthcare sector with new ratings on Insulet (PODD – Research Report), Prothena (PRTA – Research ...
Insulet forecasts total company revenue growth of 16%-20% for 2025, with Omnipod revenue growth projected at 17%-21%. U.S. Omnipod revenue is expected to grow 16%-20%, driven by the continued ramp-up ...
Supported by world-class markets data from Dow Jones and FactSet, and partnering with Automated Insights, MarketWatch ...
Hosted on MSN3d
Insulet’s (NASDAQ:PODD) Q4: Beats On Revenue, Quarterly Revenue Guidance Slightly Exceeds ExpectationsInsulin delivery company Insulet Corporation (NASDAQ:PODD) reported Q4 CY2024 results , with sales up 17.2% year on year to ...
Insulet reported a higher-than-expected profit in the fourth quarter on Thursday, driven by strong demand for its wearable insulin pumps.
Insulet Corp. (PODD) on Thursday reported fourth-quarter profit of $100.7 million. On a per-share basis, the Acton, Massachusetts-based company said it had ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results